EUVIMEDEUVIMED entdecken
Crossref

Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions

Ina Kopp, Patrick Cieslik iD, Karl Anger, Thomas Josephy, Lucca Neupert, Gunasekaran Velmurugan iD, Michael Gast, Hubert Wadepohl, Santiago Andrés Brühlmann iD, Martin Walther iD, Klaus Kopka, Michael Bachmann und 3 weitere

Inorganic Chemistry · 18.12.2023 · 62 (50) · 20754-20768

DOI: 10.1021/acs.inorgchem.3c02340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inorganic Chemistry, online erschienen am 14.09.2023. Verfasst von Ina Kopp und 14 weiteren Autor:innen. Beteiligte Einrichtung: Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany. Hauptthemen laut MEDLINE: Lanthanoid Series Elements, Actinoid Series Elements. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: Deutsche Forschungsgemeinschaft, Helmholtz Initiative and Networking Fund (Radio-Immuno-Theranostics (MHELTHERA).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Octadentate and specifically nonadentate ligands with a bispidine scaffold (3,7-diazabicyclo[3.3.1]nonane) are known to be efficiently coordinated to a range of metal ions of interest in radiopharmaceutical chemistry and lead to exceedingly stable and inert complexes. Nonadentate bispidine L2 (with a tridentate bipyridine acetate appended to N3 and a picolinate at N7) has been shown before to be an ideal chelator for 111In3+, 177Lu3+, and 225Ac3+, nuclides of interest for diagnosis and therapy, and a proof-of-principle study with an SSTR2-specific octreotate has shown potential for theranostic applications. We now have extended these studies in two directions. First, we present ligand derivative L3, in which the bipyridine acetate is substituted with terpyridine, a softer donor for metal ions with a preference for more covalency. L3 did not fulfill the hopes because complexation is much less efficient. While for Bi3+ and Pb2+ the ligand is an excellent chelator with properties similar to those of L2, Lu3+ and La3+ show very slow and inefficient complexation with L3 in contrast to L2, and 225Ac3+ is not fully coordinated, even at an increased temperature (92% radiochemical yield at 80 °C, 60 min, [L3] = 10-4 M). These observations have led to a hypothesis for the complexation pathway that is in line with all of the experimental data and supported by a preliminary density functional theory analysis, which is important for the design of further optimized bispidine chelators. Second, the coordination chemistry of L2 has been extended to Bi3+, La3+, and Pb2+, including solid state and solution structural work, complex stabilities, radiolabeling, and radiostability studies. All complexes of this ligand (La3+, Ac3+, Lu3+, Bi3+, In3+, and Pb2+), including nuclides for targeted α therapy (TAT), single-photon emission computed tomography, and positron emission tomography, are formed efficiently under physiological conditions, i.e., suitable for the labeling of delicate biological vectors such as antibodies, and the complexes are very stable and inert. Importantly, for TAT with 225Ac, the daughter nuclides 213Bi and 209Pb also form stable complexes, and this is important for reducing damage to healthy tissue.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lanthanoid Series ElementsActinoid Series ElementsChelating AgentsRadiopharmaceuticalsLigandsLeadIonsAcetatesBridged Bicyclo Compounds, Heterocyclic

Substanzen

Chelating AgentsRadiopharmaceuticalsLanthanoid Series ElementsLigandsLeadActinoid Series ElementsIonsAcetatesbispidineBridged Bicyclo Compounds, Heterocyclic

Autor:innen und Institutionen

  • Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328 Dresden, Germany.
  • Universität Heidelberg, Anorganisch-Chemisches Institut, INF 270, 69120 Heidelberg, Germany.
  • Technische Universität Dresden, Faculty of Chemistry and Food Chemistry, School of Science, 01069 Dresden, Germany.
  • National Center for Tumor Diseases (NCT) Dresden, University Hospital Carl Gustav Carus, Fetscherstraße 74, 01307 Dresden, Germany.
  • German Cancer Consortium (DKTK), Partner Site Dresden, 01307 Dresden, Germany.
  • Technische Universität Dresden, Medical Faculty Carl Gustav Carus, 01069 Dresden, Germany.

ORCID-Profile: Patrick Cieslik, Gunasekaran Velmurugan, Santiago Andrés Brühlmann, Martin Walther, Holger Stephan, Manja Kubeil, Peter Comba

Förderung

  • Deutsche Forschungsgemeinschaft
  • Helmholtz Initiative and Networking Fund (Radio-Immuno-Theranostics (MHELTHERA)

Zitieren

APA

Kopp, I., Cieslik, P., Anger, K., Josephy, T., Neupert, L., Velmurugan, G., Gast, M., Wadepohl, H., Brühlmann, S. A., Walther, M., Kopka, K., Bachmann, M., Stephan, H., Kubeil, M., & Comba, P. (2023). Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions. Inorganic Chemistry, 62(50), 20754-20768. https://doi.org/10.1021/acs.inorgchem.3c02340

Vancouver

Kopp I, Cieslik P, Anger K, Josephy T, Neupert L, Velmurugan G, et al. Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions. Inorganic Chemistry. 2023;62(50):20754-20768. doi:10.1021/acs.inorgchem.3c02340

BibTeX
@article{Kopp2023,
  author = {Kopp, Ina and Cieslik, Patrick and Anger, Karl and Josephy, Thomas and Neupert, Lucca and Velmurugan, Gunasekaran and Gast, Michael and Wadepohl, Hubert and Brühlmann, Santiago Andrés and Walther, Martin and Kopka, Klaus and Bachmann, Michael and Stephan, Holger and Kubeil, Manja and Comba, Peter},
  title = {Bispidine Chelators for Radiopharmaceutical Applications with Lanthanide, Actinide, and Main Group Metal Ions},
  journal = {Inorganic Chemistry},
  year = {2023},
  volume = {62},
  number = {50},
  pages = {20754--20768},
  doi = {10.1021/acs.inorgchem.3c02340}
}
Kostenlos starten →